Background. The use of induction therapy in pediatric heart transplantation has increased. The aim of this study was to investigate the effects of induction therapy on graft survival. Methods. The United Network for Organ Sharing database was queried for isolated pediatric heart transplants from January 1, 1994, to December 31, 2013. Propensity scores for induction treatment were calculated by estimating probability of induction using a logistic regression model. Transplants were then matched between induction treatment groups based on the propensity score, reducing potential biases. Using only propensity score matched transplants, the effect of induction therapy on graft survival was investigated using Cox-proportional hazards. Subgroup analyses were performed based on age, race, recipient cardiac diagnosis, HLA, and recipient panel-reactive antibody (PRA). Results. Of 4565 pediatric primary heart transplants from 1994 to 2013, 3741 had complete data for the propensity score calculation. There were 2792 transplants successfully matched (induction, n = 1396; no induction, n = 1396). There were no significant differences in transplant and pretransplant covariates between induction and no induction groups. In the Cox-proportional hazards model, the use of induction of was not associated with graft loss (hazard ratio [HR] , 0.88; 95% confidence interval [95% CI], 0.75-1.01; P = 0.07). In subgroup analyses, induction therapy may be associated with improved survival in patients with PRA greater than 50% (HR, 0.57; 95% CI, 0.34-0.97) and congenital heart disease (HR, 0.78; 95% CI, 0.64-0.96). Conclusions. Induction therapy is not associated with improved graft survival in primary pediatric heart transplantation. However, in pediatric heart transplant recipients with PRA greater than 50% or congenital heart disease, induction therapy is associated with improved survival. T he use of induction therapy has increased in pediatric heart transplant recipients. Although there are a multitude of induction agents, the most common induction agents are antithymocyte antibodies or IL-2 receptor antibodies. Induction therapy has been associated with decreased rejection in the first posttransplant year and death due to rejection. [1] [2] [3] [4] Also, the use of induction therapy has been described as a successful method to lead to avoidance of steroids. 5 An association between induction therapy and infection or posttransplant lymphoproliferative disorder has not been established in pediatric heart transplantation. 6 The decrease in rejection and lack of association with possible complications has led to increasing use of induction therapy. Little is known, however, of the effect of induction therapy on overall graft survival in pediatric heart transplant recipients. This study aimed to investigate the association between induction therapy and graft survival in pediatric heart transplantation.
MATERIALS AND METHODS
A retrospective analysis was performed using data obtained from the United Network for Organ Sharing (UNOS) standard transplant analysis and research files. Heart transplants performed in the United States from January 1, 1994, to December 31, 2013, were included in the analysis. The database was queried for pediatric heart transplants (age, <18 years). Transplants were included if they had valid reporting of the use of induction therapy. Transplants were excluded if they were 18 years or older, were not isolated heart transplantation, or were retransplantations. The primary endpoint was graft survival, with graft loss being defined as patient death or retransplantation. The Medical University of South Carolina Institutional Review Board approved the study. For the purposes of the study, induction therapy was defined as immunosuppressant medications given during the immediate posttransplant period (started <1 week posttransplant) that would not be part of maintenance therapy. For the purposes of this study, steroids were not considered induction therapy.
Statistical Analysis
To reduce bias from the observational study design, propensity scores were used. Using multiple pretransplant variables, logistic regression models were used to assign the probability of receiving induction therapy (Table 1 ). Due to the increase in use of induction in more recent years, year of transplant was used in the propensity score. Transplants were then 1:1 matched between each treatment group (induction vs no induction), using a "greedy" propensity score algorithm. 7 Acceptable matches were defined as transplants that had a difference between propensity scores of less than 0.2 times the standard deviation of propensity scores for the entire cohort. Only transplants that were successfully matched were used in the assessment of induction on graft survival.
To assess associations between graft survival and induction therapy, a Cox proportional hazard model was constructed.
To account for matched pairs, robust standard errors were used. 8 Covariates in the model included: transplant year, recipient on extracorporeal membrane oxygenation, recipient on ventricular assist device, underlying cardiac diagnosis, recipients most recent panel-reactive antibody (PRA), recipient age, recipient sex, recipient race, recipient on inotropes, recipient on mechanical ventilation, degree of donor-recipient HLA matching, crossmatch results, and recipient renal function. P values less than 0.05 were considered statistically significant. Secondary endpoint was 1-year survival, assessed by logistic regression analysis with the same covariates used in the Cox regression analysis.
When comparing transplant demographic and other descriptive data between induction and no induction groups, standardized differences were used. The standardized difference is the difference in the sample means divided by the pooled standard deviation. It is impervious to sample size and is not the product of significance testing based on hypotheses about populations because the goal is to examine differences between samples (not populations), P values comparing pre-and postmatch balance are intentionally not reported. As such, small standardized differences indicate that there are little differences between populations.
Subgroup Analyses
Subgroup analyses were performed based upon recipient age, recipient race, degree of HLA matching, recipient cardiac diagnosis, and recipient PRA at time of transplant. For age, transplants were divided into the following categories: less than 1 year, 1 to 10 years, and 11 to 17 years. For race, recipients were divided into white versus non-white. Cardiac diagnosis was divided into the categories: cardiomyopathy, congenital heart disease, or other. Degree of donor-recipient HLA matching was divided into the following 3 groups: no match, low match (1-2 of 6 possible matches), and high match (3-6 matches). 9 Recipient PRA was divided into the following 3 groups: less than 10%, 10-50%, and greater than 50%. In each subgroup (ie, transplant with PRA >50%), propensity matching was performed as previously described, as was the association between induction therapy and graft survival with Cox proportional hazard models. A hazard ratio (HR) was considered statistically significant if the 95% confidence interval (95% CI) did not include 1.0.
Treatment Analysis
Given the large period in which the study encompasses, 2 subsequent analysis of treatment were undertaken. In the first analysis, only induction agents that are used frequently in the current era were considered induction agents (IL-2 receptor antibodies, antithymocyte antibodies), and everyone else was considered to have not been induced. The second analysis compared survival between patients who received IL-2 receptor antibodies versus antithymocyte antibodies. In each treatment analysis, propensity score matching and Cox regression analysis was performed as previously outlined.
RESULTS
There were 4565 pediatric primary heart transplants from 1994 to 2013 in the UNOS database. Mean age for all primary heart transplants was 6.43 ± 6.23 years, 2015 (43.9%) were women, 2387 (52.0%) had cardiomyopathy, 2032 (44.3%) had a congenital heart defect. Of the 4565 Table 1 , the logistic regression model was significant compared with interceptonly model (P < 0.01). In using the matching algorithm, 2792 (61.2%) were successfully matched ( Table 2 ). The transplants which were not matched (n = 949) because these transplants were the ones in which the patients' propensity score indicated that they were either extremely likely to receive induction therapy or extremely unlikely to receive induction therapy. For the 3741 transplants with sufficient data for propensity score calculation, mean age was 6.61 ± 6.25 years, 43.6% were women, 52.3% had cardiomyopathy, and 39.2% received induction therapy. As matching occurred in a 1:1 fashion between treatment groups, both induction and no-induction groups had 1396 transplants after propensity score matching. Table 3 compares the patient characteristics between induction and no induction in all 4565 transplants, as well as those that were successfully matched. In the postmatched cohort, patient characteristics are not clinically different between groups, indicated by the low standardized differences.
For the entire cohort (n = 4565), median graft survival was 13.1 years (95% CI, 12.1-13.7 years). In the individual propensity score-matched groups, median survival was not estimable due to high levels of censoring; therefore, 1-, 5-, and 10-year survival are reported (Figure 1 ). In the induction cohort (n = 1396), 1-year survival was 91%, 5-year survival was 76%, and 10-year survival was 61%. In the induction cohort, there were 361 graft losses, with 187 (52%) having a reported cause; 38 from primary graft failure, 53 acute rejection, 56 chronic rejection/coronary artery disease, and 40 other. In the no induction cohort, 1-year survival was 88%, 5-year survival was 72%, and 10-year survival was 56%. In the no induction cohort, there were 507 graft losses, with only 204 (40%) having a reported cause; 41 primary graft failure, 46 acute rejection, 82 chronic rejection/coronary artery disease, and 35 other. The unadjusted difference in survival was statistically significant in univariate log-rank testing (P = 0.01). However, in the Cox proportional hazards model, the use of induction was not statistically associated with graft loss (HR, 0.88; 95% CI, 0.75-1.01; P = 0.07). In logistic regression analysis, 1-year survival was not associated with induction (odds ratio [OR], 1.18, 95% CI, 0.96-1.5, P = 0.11). When performing subgroup analyses, 1462 of the 2387 (61%) transplants with recipient underlying diagnosis of cardiomyopathy were able to matched. After controlling for previously mentioned covariates in the Cox-proportional hazards model, induction therapy was not associated with graft loss within this group (HR, 0.88; 95% CI, 0.7-1.1) ( Table 4) . Table 4 summarizes the results of the subgroup analyses for congenital heart disease, degree of HLA matching, race, and PRA. Of note, the only 2 groups that had hazards ratios with 95% CIs that did not include 1.0 were recipients with congenital heart disease and recipients with a PRA greater than 50%. In the congenital heart disease cohort, the HR for graft loss in those who received induction was 0.78 (95% CI, 0.64-0.96), indicating that induction therapy was associated with decreased graft loss (Figure 2 ). In the PRA greater than 50% cohort, the HR for those who received induction was 0.57 (95% CI, 0.34-0.97), also indicating that induction therapy was associated with decreased graft loss (Figure 3) . However, in the PRA less than 10% and PRA 10-50% subgroups, there was no survival benefit associated with induction. The congenital heart disease cohort were more likely to have a PRA greater than 50% compared with cardiomyopathy (OR, 8.8; 95% CI, 7.1-10.4; P < 0.01) and other diagnosis (OR, 6.1; 95% CI, 1.64-10.55; P < 0.01). Approximately 5% of the congenital heart disease patients had PRA greater than 50%.
Treatment Analysis
In the analysis of comparing patients who received contemporary induction agents (IL-2 receptor antibodies and/or Numbers in bold emphasis represent hazard ratios that 95% CI did not include 1. a Table 4 depicts results when subgroup analysis was performed, that is, 1432 patients with cardiomyopathy were propensity score matched, one half receiving induction (n = 731); then induction therapy was inserted into the multivariable Cox regression with covariates previously mentioned. The hazard ratio reported is the hazard ratio for induction in that particular subgroup, that is, in cardiomyopathy, the hazard ratio for graft loss with induction was 0.88 (95% CI, 0.7-11), but in patients with congenital heart disease, it was 0.78 (95% CI, 0.64-0.96). antithymocyte antibodies) versus other induction agents or no induction (no induction), there were 2588 successfully matched transplants. In univariate analysis, there was improved survival with modern induction compared to no induction ( Figure 4 ). However, in Cox hazard regression analysis, there was no association between contemporary induction and graft loss (HR, 0.94; 95% CI, 0.8-1.1; P = 0.49). When comparing patients who received antithymocyte antibodies versus those who received IL-2 receptor antibodies, 1070 transplants were able to be propensity score matched (535 per treatment arm). The median survival for the T cell cohort was 14.8 years versus 10.5 years for the IL-2 receptor blockers (P = 0.09) ( Figure 5) . In Cox hazards model, the IL-2 receptor blocker antibodies was more likely to suffer from graft loss compared with the antithymocyte antibody cohort (HR, 1.34; 95% CI, 1.02-1.76; P = 0.03).
DISCUSSION
Induction therapy has gained popularity, being used in 50% or more of pediatric primary transplants since 2010 up from 3% in 1994. This may be in part by a rising population of transplants in highly HLA-sensitized patients. 10 Despite the rising popularity of induction therapy, there have been very few studies investigating the effects of induction on overall graft survival in pediatric heart transplant. To the authors' knowledge, this study represents the first study to use propensity scores, therefore reducing potential biases, to assess the association of induction with graft survival in pediatric heart transplantation. Our findings indicate that induction therapy does not significantly improve overall graft survival in primary pediatric heart transplant recipients. However, recipients that had congenital heart disease or PRA greater than 50% may have improved survival with induction therapy.
Although association between induction therapy and posttransplant lymphoproliferative disorder, rejection, and infection have been well studied, induction and overall graft survival has been less studied. Boucek et al 2 studied 461 pediatric transplant recipients in the Pediatric Heart Transplant Study database, 206 of whom had received induction therapy. They concluded that induction therapy was associated with reduction in overall mortality and death due to rejection. Also, the authors stated antithymocyte antibodies had improved graft survival compared with OKT3. Our study suggests that when induction therapies are grouped together, induction therapy does not improve survival. Also, when we analyzed for contemporary induction agents (IL-2 receptor antibodies and antithymocyte antibodies) compared with less common induction agents or no induction, there was no survival benefit noted. We did find a survival benefit in antithymocyte antibodies compared to IL-2 receptor antibodies. The finding of improved survival in the antithymocyte cohort should be interpreted with caution. Similar to the Boucek et al, this comparison is based upon a small number of transplant (535 in each treatment arm). Therefore, this should be the focus of future studies, in possibly larger data sets, such as the International Society for Heart and Lung Transplantation registry.
Our study indicates that 2 subpopulations have improved graft survival when receiving induction therapy, recipients with PRA greater than 50% and patients with congenital heart disease. Both of these populations are at risk for early rejection.
11 Elevated PRA and congenital heart disease have also been associated with worse posttransplant survival.
12,13 Early rejection has been associated with worse long-term graft survival. 2, [14] [15] [16] Induction therapy has been shown to decrease the risk of early rejection in pediatric heart transplantation. 17 The survival curves in both populations show that the majority of survival benefit is in the first posttransplant year. Performing such an analysis was significantly limited in the current database by the large amount of missing reports of early rejection (30-35%). Therefore, further analysis of associations between induction and early rejection should be performed using databases with more robust reporting of early rejection, such as the Pediatric Heart Transplant Study database.
Limitations
To appropriately perform propensity score matching, all induction agents were grouped together. It is a possibility that certain induction agents are more efficacious and may provide a graft survival benefit. Also, while propensity scores assist in reducing potential biases associated with observational study designs, many transplants in the UNOS database had missing data that was required for the propensity score calculation and therefore had to be excluded from our analyses; future work might attempt to determine whether such cases could be included in these types of studies using strategies such as multiple imputation. The exclusion of multiple transplants through propensity score matching does lead to possible exclusion of data points that could alter the results. Therefore, indicating that future trials investigating the effect of induction on transplant survival should be done through a randomized clinical trial. Future studies of observational data sets should concentrate on contemporary induction agents (thymoglobulin) only. However, given the large amount of excluded transplants for propensity matching, all induction agents were investigated together. The congenital heart disease and PRA greater than 50% are colinear (ie, the PRA > 50% is more likely to have congenital heart disease). Therefore, benefits in congenital heart disease group could be from the CHD subgroup with PRA greater than 50%. To reduce this bias, PRA group was controlled for in all Cox proportional hazard models. Propensity scores help reduce biases from known and measured variables; however, unmeasured variables that could affect outcomes are not able to be adjusted for and may introduce unintended biases. Future work might also examine whether induction may be beneficial for patients receiving multiple transplants.
CONCLUSIONS
In the general population of pediatric heart transplant recipients, induction therapy is not associated with significantly improved graft survival. However, in recipients with PRA greater than 50% and congenital heart disease, induction therapy may be associated with graft survival. Therefore, indicating that induction therapy may be best used in subgroup of patients. There is a possible survival benefit of antithymocyte antibodies compared with IL-2 receptor antibodies. This information may help guide individual institutions on when to use induction therapy. These findings should be investigated further through clinical trials.
